Latest Technology Transfer News

GCM Corporation has completed the full transfer of its proprietary Very High Density (VHD) technology, gaining exclusive global ownership with payments tied to future revenue milestones.

NeuRizer Limited has secured a pivotal partnership with Reliance Industries, enabling it to resolve funding challenges and accelerate its Leigh Creek urea project. This collaboration marks a turning point for the company, allowing it to exit suspension and advance critical regulatory and operational milestones.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

NeuroScientific Biopharmaceuticals has reported promising initial clinical responses from its StemSmart™ Special Access Program treating Fistulising Crohn’s Disease, while preparing for a pivotal Phase 2 trial in 2026.

AdAlta Limited has launched its 'East to West' cellular immunotherapy operations through a strategic collaboration with Shanghai Cell Therapy Group to co-develop BZDS1901, an innovative CAR-T therapy targeting mesothelioma and other solid cancers. The company also strengthened its balance sheet by raising $2.8 million via private placements and repaying key investment agreements.

European Lithium has agreed to acquire US-based titanium company Velta Holding in an all-scrip transaction, marking a strategic diversification beyond lithium into critical materials.

AdAlta Limited and its subsidiary AdCella have partnered with Shanghai Cell Therapy Group to co-develop a pioneering CAR-T cancer therapy targeting solid tumours outside China. This collaboration aims to bring a novel, armored immunotherapy with promising clinical results to global markets.

Weebit Nano has inked a long-term licensing deal with semiconductor giant Texas Instruments to integrate its advanced ReRAM technology into TI’s embedded processing chips, marking a significant step for next-generation memory solutions.

Locate Technologies has completed its redomiciliation from Australia to New Zealand, establishing Locate NZ as the new parent company and appointing MUFG Pension & Market Services as its share registry provider.

NeuroScientific Biopharmaceuticals has initiated treatment of its fourth patient under the Special Access Scheme for StemSmart™, progressing towards a Phase 2 trial targeting severe Crohn’s disease.

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.